The effect of cannabinoid receptor agonist WIN 55,212-2 on anxiety-like behavior and locomotion in a genetic model of absence seizures in the elevated plus-maze

CNS Neurosci Ther. 2022 Aug;28(8):1268-1270. doi: 10.1111/cns.13848. Epub 2022 Apr 26.

Authors

Daniel Cassar¹, Manuela Radic¹, Maurizio Casarrubea², Vincenzo Crunelli³, Giuseppe Di Giovanni^{1

3}

Affiliations

¹ Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.
² Laboratory of Behavioral Physiology, Human Physiology Section "Giuseppe Pagano", Department of Biomedicine, Neuroscience and Advanced Diagnosistics (BIND), University of Palermo, Palermo, Italy.
³ Neuroscience Division, School of Biosciences, Cardiff University, Cardiff, UK.

Abstract

GAERS and NEC rats were treated with cannabinoid 1/2 receptor agonist WIN 55,212-2 2 mg/kg and tested on the Elevated Plus-Maze.

© 2022 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Anxiety / drug therapy
Benzoxazines / pharmacology
Benzoxazines / therapeutic use
Cannabinoid Receptor Agonists* / pharmacology
Cannabinoid Receptor Agonists* / therapeutic use
Elevated Plus Maze Test
Epilepsy, Absence*
Locomotion
Models, Genetic
Morpholines
Naphthalenes
Rats
Rats, Wistar
Seizures

Substances

Benzoxazines
Cannabinoid Receptor Agonists
Morpholines
Naphthalenes
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone